الفهرس 
Potential effects of empagliflozin in experimentally-induced hypertensive nephropathy in albino rats
ContentsOnly 14 pages are availabe for public view
 |  | from | 215 |  |  |
| | | from | 215 | | |
Abstract
Background: Owing to its huge prevalence among the population, hypertension is considered the second leading cause of end-stage renal disease (ESRD). Many factors contribute to the mechanisms involved in the development of hypertensive nephropathy (HN). These factors include an interaction between; RAAS (renin angiotensin aldosterone system), oxidative stress, endothelial dysfunction & the presence of genetic predisposition. Strict blood pressure (BP) control along with albuminuria reduction is a key factor for slowing progression of nephropathy. Aim of work: The present study was designed to evaluate the possible reno-protective effects of empagliflozin, SGLT2 inhibitor, alone and in combination with lisinopril in L-NAME-induced hypertensive nephropathy in rats. Methods: A total of 50 adult healthy male Sprague-Dawley albino rats were used in this study. HN was induced by using L-NAME (75 mg/kg/day) in rats for 6 weeks. Rats were treated orally by empagliflozin alone (10 mg/kg/day), lisinopril alone (10 mg/kg/day) and a combination of both drugs with the same previously mentioned doses. Body weight (BW) and mean arterial pressure (MAP) were measured at the start, 3rd & 6th weeks of the study. Urine volume, albumin, creatinine, glucose and sodium levels were measured also at the start, 3rd & 6th weeks of the study. Serum creatinine, urea, sodium and potassium levels were also measured at the same timings. At the end of the study, kidney weight & renal MDA were assessed as well as pathological findings of the kidneys for all groups